Nalador (Sulprostone)

Sulprostone, the active ingredient in Nalador, is a prostaglandin analog presented as an injectable solution for intravenous use. It is employed to induce labor and to prevent or treat gastric ulcer disease by enhancing gastric mucus production and stimulating uterine smooth‑muscle contraction.

GNH USA supplies Nalador as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nalador, a prostaglandin analog, is used in clinical situations that require uterine stimulation or gastric mucosal protection. - Induction of labor: stimulates uterine contractions to facilitate vaginal delivery. - Prevention and treatment of gastric ulcer: increases gastric mucus secretion to protect the stomach lining. - Management of uterine atony: promotes uterine contraction to reduce postpartum bleeding.

Adverse reactions may occur with Nalador administration.

Common Side Effects: - Nausea - Vomiting - Abdominal pain - Flushing

Serious or Rare Side Effects: - Uterine hyperstimulation leading to fetal distress - Severe hypotension - Anaphylactic or severe allergic reactions

Nalador should be used with careful clinical monitoring. - Monitor uterine activity: watch for excessive contractions. - Assess cardiovascular status: watch for hypotension. - Use cautiously in patients with asthma: risk of bronchospasm. - Avoid in individuals with known hypersensitivity to sulprostone or prostaglandin analogs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions require attention.

Major Interactions (Avoid): - Oxytocin or other uterotonic agents: may cause uterine hyperstimulation. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can diminish gastric mucosal protection.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: additive hypotensive effect. - Bronchodilators for asthma: possible bronchospasm. - Anticoagulants: monitor bleeding risk if uterine hyperstimulation occurs.